Journal of the Advanced Practitioner in Oncology最新文献

{"title":"Convergence of Hematology and Rheumatology: A Case Study.","authors":"Mariangel Prieto","doi":"10.6004/jadpro.2023.14.2.8","DOIUrl":"https://doi.org/10.6004/jadpro.2023.14.2.8","url":null,"abstract":"<p><p>Advanced practitioners may frequently encounter patients who have a hematologic and rheumatologic diagnosis. These patients are usually managed by multiple specialists, including hematologists, rheumatologists, and dermatologists, given their broad symptomatology. Genetic testing may provide the answer to the constellation of symptoms and refractory symptoms that these patients exhibit.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 2","pages":"172-175"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6c/2f/jadpro-14-172.PMC10062536.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9242327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Teclistamab-cqyv: The First Bispecific T-Cell Engager Antibody for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma.","authors":"Gwen Hua,&nbsp;Ryan Scanlan,&nbsp;Rachael Straining,&nbsp;Daniel S Carlson","doi":"10.6004/jadpro.2023.14.2.7","DOIUrl":"https://doi.org/10.6004/jadpro.2023.14.2.7","url":null,"abstract":"<p><p>Multiple myeloma (MM) remains an incurable malignancy originating from plasma cells. Despite significant advances in treatment, relapses remain inevitable, and novel therapies continue to be needed. Teclistamab-cqyv is a first-in-class, bispecific T-cell engager (BiTE) antibody for the treatment of MM. Teclistamab-cqyv activates the immune system by binding to the cluster of differentiation 3 (CD3) receptor expressed on the surface of T cells and to the B-cell maturation antigen (BCMA) expressed on the surface of MM cells and some healthy B-lineage cells. Teclistamab-cqyv has been shown to be effective in a pivotal trial that demonstrated an overall response rate of more than 60% in heavily pretreated patients. Compared with other BCMA-targeted agents, the side effect profile of teclistamab-cqyv suggests a more tolerable option for elderly patients. Teclistamab-cqyv is now approved by the US Food and Drug Administration (FDA) as monotherapy for the treatment of adult patients with relapsed or refractory MM.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 2","pages":"163-171"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3e/06/jadpro-14-163.PMC10062534.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9242325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integration of an APP-Led Supportive and Palliative Oncology Care Program: A Quality Improvement Project.","authors":"Cecilia Motschenbacher,&nbsp;Tanya Cohn","doi":"10.6004/jadpro.2023.14.2.2","DOIUrl":"https://doi.org/10.6004/jadpro.2023.14.2.2","url":null,"abstract":"<p><p>Patients with advanced cancer have been found to demonstrate severe symptoms and low quality of life at diagnosis; therefore, it is imperative that they have early access to palliative care services along the continuum of care. Oncology advanced practice providers are uniquely poised to serve as champions for primary palliative care integration within their practice. The purpose of this quality improvement project was to develop and implement an APP-led supportive and palliative oncology care (SPOC) program within routine cancer care. The project design utilized the Plan-Do-Study-Act (PDSA) methodology as the guiding framework for development, implementation, and analysis of the SPOC program. Across 49 participants, there were a total of 239 SPOC encounters during the studied period. Participants had a mean of 4.9 visits (<i>SD</i> = 3.5) with the APP. There was a high prevalence of patient-reported symptom burden, the most frequent of which included pain at 44 (90%), fatigue at 36 (74%), appetite loss at 29 (59%), and weakness at 27 (55%) instances. Ninety-four percent of participants (<i>n</i> = 46) had a structured and documented goals of care conversation with the APP during their participation within the program. A total of seven patients completed their advance directives while receiving SPOC care, which was a 25% completion rate. There was a significant demand for interdisciplinary resources (<i>n</i> = 136). Integration of SPOC principles into routine oncology practice is an opportunity to improve the patient and family experience while demonstrating the value of APPs at the clinical and organizational level.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 2","pages":"118-125"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/25/f2/jadpro-14-118.PMC10062537.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9242326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tisotumab Vedotin Safety and Tolerability in Clinical Practice: Managing Adverse Events.","authors":"Courtney R Arn,&nbsp;Kimberly J Halla,&nbsp;Sally Gill","doi":"10.6004/jadpro.2023.14.2.4","DOIUrl":"https://doi.org/10.6004/jadpro.2023.14.2.4","url":null,"abstract":"<p><p>Tisotumab vedotin-tftv, an antibody-drug conjugate indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy, demonstrated clinically meaningful and durable responses with a manageable safety profile in the pivotal phase II innovaTV 204 clinical trial. Based on the proposed mechanism of action of tisotumab vedotin, experience from clinical trials, and the US prescribing information, certain adverse events (AEs) including ocular AEs, peripheral neuropathy, and bleeding have been identified as AEs of interest. This article highlights practical considerations and provides recommendations to support the management of selected AEs associated with tisotumab vedotin. Central to monitoring of patients on tisotumab vedotin is a comprehensive care team comprised of oncologists, advanced practice providers (including nurse practitioners, physician assistants, and pharmacists), and other specialists such as ophthalmologists. As ocular AEs may be less familiar to gynecologic oncology practitioners, adherence to the \"Premedication and Required Eye Care\" section outlined in the US prescribing information, as well as the incorporation of ophthalmologists into the oncology care team, can help provide timely and appropriate eye care for patients receiving tisotumab vedotin.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 2","pages":"139-152"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c1/ea/jadpro-14-139.PMC10062530.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9248454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical Activity in Multiple Myeloma: A Review of the Current Literature.","authors":"Michaela Hillengass,&nbsp;Janine Joseph,&nbsp;Jane Mccarthy,&nbsp;Jens Hillengass","doi":"10.6004/jadpro.2023.14.2.5","DOIUrl":"https://doi.org/10.6004/jadpro.2023.14.2.5","url":null,"abstract":"<p><p>One of the major issues patients with multiple myeloma (MM) suffer from is bone instability and the resulting difficulties that come along with it, such as pain and immobility. Few studies have been performed in this patient group to investigate the effects of physical exercise on outcomes such as muscle strength, quality of life, fatigue, and pain. A PubMed search was conducted by entering the search terms \"multiple myeloma\" and \"exercise,\" and \"multiple myeloma\" and \"physical activity\" that yielded 178 and 218 manuscripts, respectively. Limiting the search results to clinical trials left 13 and 14 manuscripts, respectively, and 7 studies (1 retrospective chart review, 1 questionnaire study, and 5 prospective clinical trials). The majority of these studies (5) were published in the past decade. The outcomes of several studies of exercise in MM show that physical exercise is feasible for MM patients. Compared with the control groups, the most active participants show better outcomes, such as improvements in their blood counts and in quality-of-life parameters such as fatigue, pain, sleep, and mood. One trial found that MM patients were in much poorer condition than people in a normative standard group. Some of the reported outcomes of exercise in MM have been promising but need to be substantiated in a broader setting with more diverse participants, for a longer duration, and include more endpoints. Due to the disease-inherent risk of bone-related complications, an individualized, supervised training protocol could be a preferable tool.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 2","pages":"153-158"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/74/c1/jadpro-14-153.PMC10062531.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9242323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using Pleomorphic Adenoma Gene 1 (<i>PLAG1</i>) to Distinguish Carcinoma of the Parotid Gland From Primary Lung Cancer: A Case Study.","authors":"Avigayil East","doi":"10.6004/jadpro.2023.14.2.6","DOIUrl":"https://doi.org/10.6004/jadpro.2023.14.2.6","url":null,"abstract":"<p><p>A 40-year-old female never-smoker with no significant medical history presented with right-side facial swelling and 3 months of progressive, radiating otalgia. This article reviews the case of a young woman with carcinoma ex pleomorphic adenoma (CXPA) and the pathway to arrive at the diagnosis.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 2","pages":"159-161"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a1/8d/jadpro-14-159.PMC10062535.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9248452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of Distress and Support Group Participation in Caregivers of Older Allogeneic Hematopoietic Cell Transplantation Patients: A Single Institution Retrospective Review.","authors":"Theresa A Elko,&nbsp;Samantha Brown,&nbsp;Stephanie Lobaugh,&nbsp;Sean Devlin,&nbsp;Ann A Jakubowski,&nbsp;Miguel-Angel Perales,&nbsp;Molly A Maloy,&nbsp;Allison J Applebaum,&nbsp;Sergio A Giralt,&nbsp;Lauren Levy,&nbsp;Anne Schneider,&nbsp;Richard J Lin","doi":"10.6004/jadpro.2023.14.2.3","DOIUrl":"https://doi.org/10.6004/jadpro.2023.14.2.3","url":null,"abstract":"<p><p>Older patients with hematologic malignancies are increasingly considered for allogeneic hematopoietic cell transplant (allo-HCT). However, older patients often have increased comorbidities and thus may require an increased level of post-transplant care. These factors can contribute to increased caregiver distress, which has been associated with worsened health outcomes for caregivers and patients. To examine predictors of caregiver distress and support group participation in caregivers of older allo-HCT patients, we retrospectively reviewed charts of 208 patients aged 60 and older who underwent their first allo-HCT at our institution from 2014 through 2016. We systematically characterized and identified the incidence of caregiver distress and attendance in a caregiver support group from the start of conditioning through 1 year post allo-HCT. Evidence of caregiver distress and support group participation was recorded by reviewing clinical and/or social work documentation. We found that 20 caregivers (10%) endorsed stress and 44 caregivers (21%) attended our support group at least once. A patient's prior history of psychiatric diagnosis (<i>p</i> = .046) or the use of potentially inappropriate medications for older adults (<i>p</i> = .046) was found to be associated with caregiver stress. Caregivers who were spouses or partners of patients (<i>p</i> = .048) or caregivers of married patients were more likely to attend the support group (<i>p</i> = .007). While limited by retrospective design and likely underreporting, this study reveals factors associated with caregiver distress in the older allo-HCT caregiver population. This information can help providers identify caregivers at risk for distress and improve caregiver resources, which may improve both caregiver and patient outcomes.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 2","pages":"127-137"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/56/6d/jadpro-14-127.PMC10062532.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9337514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Importance of Professional Communities and Collaborations.","authors":"Beth Faiman","doi":"10.6004/jadpro.2023.14.2.1","DOIUrl":"https://doi.org/10.6004/jadpro.2023.14.2.1","url":null,"abstract":"The complexity of cancer care requires unique skill sets that must be cultivated. Collaborating with professionals specializing in different areas ensures comprehensive and patient-centered care. A multidisciplinary approach can lead to a better understanding of a patients’ needs, better outcomes, and more effective treatment plans. Every discipline has a unique perspective and expertise to contribute. Hopefully you will find trusted peers and form connections in your area to help you practice at the top of your scope and enhance patient care.","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 2","pages":"115-116"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/88/ed/jadpro-14-115.PMC10062533.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9248453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced Practice Provider Model for Urgent Oncology Care.","authors":"Marie Iannelli,&nbsp;Alexis Brimm-Akins,&nbsp;Anessa M Foxwell,&nbsp;Beth Sandy,&nbsp;Krista Winalski,&nbsp;Kara Gatto,&nbsp;Suzanne Mcgettigan,&nbsp;Carolyn Grande","doi":"10.6004/jadpro.2023.14.1.7","DOIUrl":"https://doi.org/10.6004/jadpro.2023.14.1.7","url":null,"abstract":"<p><p>Inherent to the cancer disease trajectory are heightened risks for a plethora of comorbid diagnoses. As the treatment landscape for oncology therapeutics continues to rapidly advance, patients are living longer and potentially experiencing more symptoms requiring rapid assessment. Prompt assessment and intervention for cancer or cancer treatment-related symptoms is imperative to achieve patient comfort and obtain the best overall patient outcomes. Traditionally, these patients were frequently referred to the emergency department (ED) when same-day clinic appointments were not obtainable. In order to decrease ED utilization and provide same-day urgent care for oncology patients, the Abramson Cancer Center established an advanced practice provider-led Oncology Evaluation Center where cancer patients are able to receive same-day assessment, symptom relief, and ultimately prevent unnecessary ED visits.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 1","pages":"73-81"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/11/cb/jadpro-14-73.PMC9894209.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9213142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serious Illness Conversation Training for Inpatient Medical Oncology Advanced Practice Providers: A Quality Improvement Project.","authors":"Jo Clarke, Mary Alice Momeyer, Robin Rosselet, Loraine Sinnott, Janine Overcash","doi":"10.6004/jadpro.2023.14.1.3","DOIUrl":"10.6004/jadpro.2023.14.1.3","url":null,"abstract":"<p><strong>Background: </strong>Hospitalized advanced cancer patients and their families are inadequately informed about their cancer diagnosis and prognosis, which limits educated and reasonable decision-making for their care and end-of-life planning.</p><p><strong>Objectives: </strong>The primary objective of this evidence-based project was to enhance serious illness conversations (SICs) with advanced cancer patients by providing advanced practice providers (APP) training and to increase the frequency of SIC documentation in the electronic medical record (EMR).</p><p><strong>Methods: </strong>SIC training included a 45-minute Zoom video recording and 30-minute discussion groups. Advanced practice providers' beliefs and self-efficacy were measured pre- and post-training via a survey. Prior training was queried in the pre-survey. Data from APP discussion groups were summarized and themes identified. Serious illness conversation documentation frequency was measured. Pre- and post-survey differences were assessed using Wilcoxon rank sum tests.</p><p><strong>Findings: </strong>19 inpatient medical oncology nurse practitioners and 6 physician assistants participated. Many reported little formal training yet are engaging in SICs regularly. Scores on both the belief and self-efficacy survey sections were high prior to training and did not significantly change following training. Despite the high pre-survey scores, many of the APPs verbalized the need for more training to improve their confidence and to learn SIC communication skills. Training significantly improved the APP's ability to manage their own emotions and be present. This indicates a trend toward improved APP comfort with SICs. Accessible documentation in the EMR increased with training.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 1","pages":"37-48"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ef/9c/jadpro-14-37.PMC9894205.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10716079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}